ArticleNature medicine2018
Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection.
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 238 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
238 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The impact of analytical treatment interruptions and trial interventions on time to viral re-suppression in people living with HIV restarting ART in cure-related clinical studies: a systematic review and meta-analysis.Journal of the International AIDS Society · 2024Pooled it
- Initiation of Antiretroviral Therapy during Primary HIV Infection: Effects on the Latent HIV Reservoir, Including on Analytic Treatment Interruptions.AIDS reviews · 2020Pooled it
- Trial
- Long-term effect of temporary ART initiated during primary HIV-1 infection on viral persistence.Nature communications · 2025Trial
- Paradoxically Greater Persistence of HIV RNA-Positive Cells in Lymphoid Tissue When ART Is Initiated in the Earliest Stage of Infection.The Journal of infectious diseases · 2022Trial
- Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound.Scientific reports · 2022Trial
- Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection.The Journal of clinical investigation · 2022Trial
- Kinetics of Plasma HIV Rebound in the Era of Modern Antiretroviral Therapy.The Journal of infectious diseases · 2020Trial
- HIV-1 variants are archived throughout infection and persist in the reservoir.PLoS pathogens · 2020Trial
- Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption.The Journal of clinical investigation · 2020Trial
- Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound.The Journal of clinical investigation · 2020Trial
- Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.Nature medicine · 2020Trial
- Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART.JCI insight · 2020Trial
- Serologic evidence of mpox virus exposure among people living with human immunodeficiency virus in Thailand predating clinical recognition during the 2022 outbreak.IJID regions · 2026Article
- HIV superinfection reveals sequential reservoir reactivation and immune-driven rebound dynamics.Journal of virology · 2026Article
- The rebound-initiating viral reservoir (RIVR) in SIV/SHIV infection is dominated by plasma virus sequences present at the time of ART initiation.Journal of virology · 2026Article
- Unique CD8bioRxiv : the preprint server for biology · 2026Article
- The HIV-1 restriction factor RPRD2 does not inhibit transcription of HIV-1 or endogenous retroelements.bioRxiv : the preprint server for biology · 2026Article
- Early intervention, lasting impact: benefits of early antiretroviral therapy and implications for posttreatment control.Current opinion in HIV and AIDS · 2026Review
- Central Nervous System HIV Persistence and Clinical Consequences During Suppressive ART.Current HIV/AIDS reports · 2026Review
178 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
Antiretroviral therapy during the earliest stage of acute HIV infection (Fiebig I) might minimize establishment of a latent HIV reservoir and thereby facilitate viremic control after analytical treatment interruption. We show that 8 participants, who initiated treatment during Fiebig I and were treated for a median of 2.8 years, all experienced rapid viral load rebound following analytical treatment interruption, indicating that additional strategies are required to control or eradicate HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.